Literature DB >> 11061762

Economic impact of influenza vaccination in preschool children.

G M Cohen1, M D Nettleman.   

Abstract

OBJECTIVE: The economic impact of routine vaccination of preschool children with inactivated influenza vaccine was investigated.
DESIGN: A decision analysis was performed using data from the literature. Direct and indirect costs of each vaccination strategy were calculated and compared with a strategy of not vaccinating.
SETTING: Two settings were evaluated: a setting in which vaccination was available during flexible hours and a setting in which vaccination was available only during usual work hours (8:00 am-5:00 pm).
RESULTS: Vaccination resulted in a net cost savings in both settings. The net savings per vaccine recipient were $21.28 in the flexible setting and $1.20 in the restricted setting. Although the analysis was performed for the inactivated vaccine, sensitivity analysis showed that the nasal vaccine could also result in a net cost savings depending on the price of the cold-adapted vaccine when it is licensed.
CONCLUSION: Vaccinating preschool children is economically advantageous. Serious consideration should be given to recommending vaccination in this age group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061762     DOI: 10.1542/peds.106.5.973

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  27 in total

1.  Influenza vaccination: financial burden or public health solution?

Authors:  Marina V Zeltser
Journal:  Biotechnol Healthc       Date:  2009-10

Review 2.  Economic evaluations of childhood influenza vaccination: a critical review.

Authors:  Anthony T Newall; Mark Jit; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

3.  Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts.

Authors:  Terho Heikkinen; Robert Booy; Magda Campins; Adam Finn; Per Olcén; Heikki Peltola; Carlos Rodrigo; Heinz-Josef Schmitt; Fabian Schumacher; Stephen Teo; Catherine Weil-Olivier
Journal:  Eur J Pediatr       Date:  2005-12-21       Impact factor: 3.183

4.  Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.

Authors:  S L Lee; P Etches; J L Robinson
Journal:  Paediatr Child Health       Date:  2001-10       Impact factor: 2.253

5.  Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness.

Authors:  Jessie R Chung; Brendan Flannery; Manjusha Gaglani; Michael E Smith; Evelyn C Reis; Robert W Hickey; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; Emily T Martin; Hannah E Segaloff; Sara S Kim; Manish M Patel
Journal:  JAMA Pediatr       Date:  2020-07-01       Impact factor: 16.193

6.  Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.

Authors:  Luis Salleras; Encarna Navas; Nuria Torner; Andreu A Prat; Patricio Garrido; Núria Soldevila; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

7.  Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs.

Authors:  Yoko Ibuka; A David Paltiel; Alison P Galvani
Journal:  Med Decis Making       Date:  2012-04-03       Impact factor: 2.583

8.  Employer-incurred health care costs and productivity losses associated with influenza.

Authors:  Sudeep Karve; Derek A Misurski; Genevieve Meier; Keith L Davis
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

Review 9.  Role of influenza vaccine for healthy children in the US.

Authors:  Stan L Block
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.

Authors:  Nicole E Basta; Dennis L Chao; M Elizabeth Halloran; Laura Matrajt; Ira M Longini
Journal:  Am J Epidemiol       Date:  2009-08-13       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.